Lead Product(s): GB0139
Therapeutic Area: Pulmonary/Respiratory Diseases
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
The results showed that GB0139 is highly effective in the bleomycin model, including pharmacodynamic evidence with reduction of galectin-3.